JJJingxian Jiang

Jingxian Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jingxian Jiang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Jingjing Wu

    Department of Respiratory and Critical Care Medicine The First Affiliated Hospital of Nanjing Medical University Nanjing China

    2 shared publications
  • Mao Huang

    Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

    2 shared publications
  • Mingshun Zhang

    Jiangsu Province Engineering Research Center of Antibody Drug, NHC Key Laboratory of Antibody Technique, Department of Immunology, Nanjing Medical University, Nanjing, China

    2 shared publications
  • Ningfei Ji

    Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

    2 shared publications
  • Qiyun Ma

    Department of Respiratory and Critical Care Medicine The First Affiliated Hospital of Nanjing Medical University Nanjing China

    2 shared publications
  • Xinyu Jia

    Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

    2 shared publications

Latest Publications

  • Open Access

    Plasma sCD146 is a potential biomarker for acute exacerbation of chronic obstructive pulmonary disease

    by Xinyu Jia, Jingxian Jiang, Chen Yang, Sujuan Zhang, Jingjing Wu, Qiyun Ma, Zhengxia Wang, Zhongqi Chen, Mingshun Zhang, Mao Huang, et al.

    This study examined the levels of soluble CD146 (sCD146) in plasma samples from patients with chronic obstructive pulmonary disease (COPD) and assessed the relationship between sCD146 and the severity of COPD. A total of 97 COPD patients were recruited from 20 medical centers in Jiangsu, China, including 13 stable subjects and 84 exacerbated subjects. The plasma sCD146 level in exacerbated subjects (28.77 ± 10.80 ng/mL) was significantly lower than that in stable subjects (38.84 ± 15.00 ng/mL). In the high sCD146 group, the proportion of subjects with modified Medical Research Council (mMRC) scores of 0–1 was higher, the proportion of subjects with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 4 was lower, and the proportion of subjects with ≥1 hospitalizations in the past year was lower. The plasma sCD146 level was negatively correlated with the COPD Assessment Test (CAT) score (r = −0.2664, p = 0.0087). Logistic regression analysis showed that sCD146 was an independent risk factor for acute exacerbation of COPD (AECOPD). Receiver operating characteristic (ROC) analysis suggested that sCD146 combined with sex, age, pulmonary function, and acute exacerbations in the past year had clinical value for the accurate identification of AECOPD, with an area under the ROC curve (AUC) of 0.908 (95% CI: 0.810–1.000, p < 0.001). In addition, there was a significant negative correlation between plasma sCD146 and S100A9 (r = −0.3939, p < 0.001).


  • Open Access

    LincR-PPP2R5C Promotes Th2 Cell Differentiation Through PPP2R5C/PP2A by Forming an RNA–DNA Triplex in Allergic Asthma

    by Ningfei Ji, Zhongqi Chen, Zhengxia Wang, Wei Sun, Qi Yuan, Xijie Zhang, Xinyu Jia, Jingjing Wu, Jingxian Jiang, Meijuan Song, et al.

    Ji N, et al. Allergy Asthma Immunol Res. 2024 Jan;16(1):71-90. https://doi.org/10.4168/aair.2024.16.1.71